Project Grant R01AI191459
- Federal Grant Award Summary The University of California, San Diego received a $438,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 21, 2025, with a completion date of June 30, 2027. This award supports research to develop new tools and methodologies that facilitate drug discovery targeting pathogen proteasomes, with particular application to parasitic diseases...
- Federal Project Grant Award Summary The University of California, San Diego received a $3,082,513 Project Grant awarded July 18, 2025, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). This four-year award, with completion targeted for June 30, 2029, supports research to optimize lipid prodrug delivery strategies for remdesivir nucleoside monophosphate (RVN-MP) and broad-spectrum nucleoside antivirals....
- Federal Project Grant Award Summary The University of California, San Diego received a $395,692 Project Grant award dated July 17, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports a five-year research initiative extending through June 30, 2030, titled "Enhancing Bacteriophage Function with Coevolution and Synthetic Biology." This project addresses the critical public...
- Federal Grant Award Summary The University of California, San Diego received a $3.19 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 16, 2025, with a completion date of June 30, 2029. This award supports biomedical research investigating the roles and regulation of tissue-resident CD8 T cells during persistent viral infections, specifically utilizing a mouse...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a Project Grant totaling $588,514 under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of July 21, 2025 and ultimate completion date of June 30, 2030. This five-year research initiative will develop conditional and female-lethal gene drive technologies to improve population suppression of Aedes aegypti, a critical...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $438,500 to the University of California, San Diego for a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective July 8, 2025, with a completion date of June 30, 2027. The research project focuses on characterizing sequence-specific determinants and impacts of NS2 (non-structural protein 2) interactions with the influenza A virus (IAV) polymerase...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $492,000 to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 1, 2025, for a five-year project period extending through July 31, 2030. This Project Grant supports biochemical and structural characterization research of the elongasome and divisome protein complexes in Mycobacterium tuberculosis (MTB) and...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $616,588 to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 6, 2025, for a project extending through May 31, 2030. This Project Grant funds research to develop a high-precision phenotypic map of Cryptococcus neoformans, a fungal pathogen responsible for over 100,000 annual meningitis fatalities...
- Federal Grant Award Summary The University of California, San Diego received a $3.02 million Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 8, 2025, with a completion date of June 30, 2029. This award funds a four-year basic science research project investigating the regulatory T (Treg) cell-derived interleukin-27 (IL-27) axis and its role in immune regulation, particularly in...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Illinois a $440,908 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 5, 2026, with a completion date of January 31, 2028. The award funds research to develop extracellular vesicle-inspired nano vesicles capable of delivering CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) ribonucleoprotein complexes to...
The University of California, San Diego received a $720,035 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 2, 2026, through January 31, 2031. The award funds development and research of an innovative therapeutic platform termed "living microrobot therapeutics" designed to treat severe multidrug-resistant (MDR) pulmonary infections, particularly ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA). The research platform combines Chlamydomonas reinhardtii microalgae modified with neutrophil membrane-coated, drug-loaded polymeric nanoparticles (designated "algae-NP-robots") to deliver therapeutic agents directly to infected lung tissue. The microalgae component enhances drug penetration and retention within the lungs, while the neutrophil membrane coating reduces immune clearance, enables pathogen-specific binding, and functions as a "nanosponge" to neutralize excessive pro-inflammatory cytokines. This dual-mechanism approach represents an advanced drug delivery system intended to improve treatment outcomes for critically ill patients with severe bacterial pulmonary infections that are increasingly resistant to conventional antibiotic therapies.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $720.0k | 2/2/26 |